Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

作者：Li J, Zhenghang Wang, Jing Huang, Yi Ba, Baoshan Cao, Suxia Luo, Wenhua Li, Chunmei Bai, Zhengbo Song, Jianping Xiong, Liangjun Zhu, Guangyu An, Yanqiao Zhang, Zhi‐Hua Li, Yongsheng Li, Yanhong Gu, Changlu Hu, XingYa Li, Chenghui Huang, Qihan Fu, Xianli Yin, Xinjun Liang, Diansheng Zhong, Huaqiu Shi, Xiaoyan Li, Zhen Li, Lian Liu, Feng Wang, Rong Liang, Guohao Xia, Zhen Wang, Andrea Wang‐Gillam, Yuli Ding, Zhiyue Rao, Wenhui Pan, Shuang Lü, Xin Sun, Lin Shen · 发表于：˜The œLancet. Gastroenterology & hepatology · 年份：2025 · DOI：10.1016/s2468-1253(25)00267-5 · 被引用次数：2 · 研究领域：Colorectal Cancer Treatments and Studies、Lung Cancer Treatments and Mutations、PI3K/AKT/mTOR signaling in cancer